OncLive TV

Emily Hinchcliff, MD, MPH, discusses the addition of dostarlimab to standard-of-care chemotherapy in patients with advanced/recurrent endometrial cancer.

Guillermo Garcia-Manero, MD, discusses the rationale for investigating the dual inhibition of IRAK4 and FLT3 with emavusertib in MDS and AML

Scott Kopetz, MD, PhD, FACP, discusses findings from the phase 3 BREAKWATER study of frontline encorafenib plus cetuximab with or without chemotherapy in BRAF V600E–mutated metastatic CRC.

Gao-Jun Teng, MD, discusses findings from the phase 2 CARES-005 trial of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable HCC.

Emily M. Hinchcliff, MD, MPH, discusses future research directions regarding the role of PARP inhibitors for the treatment of patients with ovarian cancer.

Alvaro Alencar, MD, explains the rationale of a phase 1 trial investigating NX-5948, a BTK degrader, in chronic lymphocytic leukemia.

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab plus chemotherapy for metastatic gastric or GEJ adenocarcinoma.

Mohammed Najeeb Al Hallak, MD, MS, discusses treatment considerations for patients with HCC and the associated risks of cirrhosis and portal hypertension.

Alberto Montero, MD, MBA, CPHQ, discusses unmet treatment needs for patients with HER2-positive metastatic breast cancer.

Wojciech Jurczak, MD, discusses the role of nemtabrutinib in the management of relapsed or refractory follicular lymphoma.

Adam E. Singer, MD, PhD, discusses factors that inform the choice between IO/IO and IO/TKI regimens for patients with renal cell carcinoma.

John M. Burke, MD, discusses the barriers to initiating venetoclax-based regimens for chronic lymphocytic leukemia.

Bradley McGregor, MD, discusses next steps for research with ipilimumab plus nivolumab for patients with diverse bladder cancer histologies.

Ira Zackon, MD, discusses the real-world use of bispecific antibodies for patients with R/R multiple myeloma in the community oncology setting.

Jacob E. Berchuck, MD, shares next steps in research for a novel epigenomic liquid biopsy test for detecting PSMA in castration-resistant prostate cancer.

David A. Braun, MD, PhD, discusses future directions for research into protein glycosylation as a biomarker of response in renal cell carcinoma.

Judy Hayek, MD, explains the rationale of a retrospective analysis evaluating laparoscopic vs open surgery in advanced ovarian cancer.

Paolo Ghia, MD, PhD, discusses future research directions and potential roles for first-line, fixed-duration ibrutinib plus venetoclax in CLL.

Nicole Odzer discusses the utility of ERBB2 copy number ratio as a predictive biomarker in HER2+ breast cancer.

Robert M. Rifkin, MD, FACP, offers advice to colleagues about belantamab mafodotin as a treatment option for patients with relapsed/refractory multiple myeloma.

Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell therapy and ongoing efforts to expand its application beyond B-cell malignancies.

Jian Zhang, MD, discusses SIM0270, a brain-penetrant oral SERD, in combination with everolimus, in ER-positive, HER2-negative advanced breast cancer.

Carsten Niemann, MD, PhD, discusses long-term follow-up data from the phase 3 GLOW trial evaluating fixed-duration ibrutinib plus venetoclax in CLL.

Jae Park, MD, discusses the FDA approval of obe-cel for adult patients with relapsed or refractory acute lymphoblastic leukemia.

David A. Braun, MD, PhD, discusses the potential use of protein glycosylation as a biomarker of response in renal cell carcinoma.

Bradley McGregor, MD, discusses the rationale for investigating nivolumab plus ipilimumab in advanced, rare genitourinary malignancies.

Francisco J. Hernandez-Ilizaliturri, MD, discusses findings from a study investigating immunologic changes in patients with CLL treated with venetoclax.

Rahul Banerjee, MD, FACP, discusses treatment de-escalation strategies with the use of bispecific antibodies in patients with relapsed multiple myeloma.

Monica H. Vetter, MD, on the implications for inclusion criteria for insurance approvals for pembrolizumab- and dostarlimab-based regimens in endometrial cancer.